-
Je něco špatně v tomto záznamu ?
Life expectancy in glioblastoma patients who had undergone stereotactic biopsy: a retrospective single-center study
M. Halaj, O. Kalita, L. Tuckova, L. Hrabalek, M. Dolezel, J. Vrbkova
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2001
Free Medical Journals
od 1998
Medline Complete (EBSCOhost)
od 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
od 2001
PubMed
37431620
DOI
10.5507/bp.2023.030
Knihovny.cz E-zdroje
- MeSH
- biopsie metody MeSH
- dospělí MeSH
- glioblastom * mortalita patologie terapie MeSH
- lidé středního věku MeSH
- lidé MeSH
- magnetická rezonanční tomografie MeSH
- naděje dožití * MeSH
- nádory mozku * mortalita patologie terapie MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- stereotaktické techniky * MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
OBJECTIVE: The best results in glioblastoma (GBM) are obtained through aggressive treatment comprising maximally radical but safe resection followed by chemoradiotherapy. However, certain patients will undergo only stereotactic biopsy. This paper aims to evaluate life expectancy in GBM patients who underwent only stereotactic biopsy, including the effect of subsequent oncological treatment. PATIENTS AND METHODS: Patients with confirmed GBM histology who had undergone stereotactic biopsy between June 2006 and December 2016 were retrospectively selected. Each patient had received a CT scan, followed by an MRI scan with a contrast agent. None of the patients were amenable to microsurgical resection. RESULTS: Of the 60 patients, 41 (69%) received no subsequent oncological treatment, while 14 (23%) underwent isolated radiotherapy. Mean survival time of all patients was 2.8 months. Those who received no additional treatment had an average survival time of 2.3 months; patients who received any type of oncological treatment was 3.7 months. Of these, those receiving radiotherapy alone had a mean survival of 3.1 months. Patients who received oncological treatment with the Stupp protocol had a survival time of 6.6 months. CONCLUSION: Diagnostic and surgical advances related to GBM treatment mean that radical resections can be performed even in eloquent brain areas. However, patients not indicated for resection will experience a major reduction in life expectancy. Patients who underwent stereotactic biopsy and received some form of oncological treatment experienced slightly increased overall survival relative to patients with a natural disease course. Patients with favorable clinical factors reacted better to treatment.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24022790
- 003
- CZ-PrNML
- 005
- 20250521143041.0
- 007
- ta
- 008
- 241205s2024 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2023.030 $2 doi
- 035 __
- $a (PubMed)37431620
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Halaj, Matej $u Department of Neurosurgery, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0240119
- 245 10
- $a Life expectancy in glioblastoma patients who had undergone stereotactic biopsy: a retrospective single-center study / $c M. Halaj, O. Kalita, L. Tuckova, L. Hrabalek, M. Dolezel, J. Vrbkova
- 520 9_
- $a OBJECTIVE: The best results in glioblastoma (GBM) are obtained through aggressive treatment comprising maximally radical but safe resection followed by chemoradiotherapy. However, certain patients will undergo only stereotactic biopsy. This paper aims to evaluate life expectancy in GBM patients who underwent only stereotactic biopsy, including the effect of subsequent oncological treatment. PATIENTS AND METHODS: Patients with confirmed GBM histology who had undergone stereotactic biopsy between June 2006 and December 2016 were retrospectively selected. Each patient had received a CT scan, followed by an MRI scan with a contrast agent. None of the patients were amenable to microsurgical resection. RESULTS: Of the 60 patients, 41 (69%) received no subsequent oncological treatment, while 14 (23%) underwent isolated radiotherapy. Mean survival time of all patients was 2.8 months. Those who received no additional treatment had an average survival time of 2.3 months; patients who received any type of oncological treatment was 3.7 months. Of these, those receiving radiotherapy alone had a mean survival of 3.1 months. Patients who received oncological treatment with the Stupp protocol had a survival time of 6.6 months. CONCLUSION: Diagnostic and surgical advances related to GBM treatment mean that radical resections can be performed even in eloquent brain areas. However, patients not indicated for resection will experience a major reduction in life expectancy. Patients who underwent stereotactic biopsy and received some form of oncological treatment experienced slightly increased overall survival relative to patients with a natural disease course. Patients with favorable clinical factors reacted better to treatment.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a glioblastom $x mortalita $x patologie $x terapie $7 D005909
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a naděje dožití $7 D008017
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a nádory mozku $x mortalita $x patologie $x terapie $7 D001932
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a biopsie $x metody $7 D001706
- 650 12
- $a stereotaktické techniky $7 D013238
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a magnetická rezonanční tomografie $7 D008279
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Kalita, Ondřej, $d 1972- $u Department of Neurosurgery, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $u Department of Health Care Sciences, Faculty of Humanities, Tomas Bata University, Zlin, Czech Republic $7 xx0046875
- 700 1_
- $a Tučková, Lucie $u Department of Pathology and Laboratory of Molecular Pathology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0238007
- 700 1_
- $a Hrabálek, Lumír $u Department of Neurosurgery, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0076898
- 700 1_
- $a Doležel, Martin $u Department of Oncology, University Hospital Olomouc and Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0075943
- 700 1_
- $a Vrbková, Jana, $d 1971- $u Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic $7 xx0105359
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 168, č. 4 (2024), s. 349-353
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37431620 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20241205 $b ABA008
- 991 __
- $a 20250521143039 $b ABA008
- 999 __
- $a ok $b bmc $g 2324815 $s 1234795
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 168 $c 4 $d 349-353 $e 20230710 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $n Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub $x MED00012606
- LZP __
- $b NLK124 $a Pubmed-20241205